Shanghai Junshi Biosciences Co., Ltd.

Symbol: 1877.HK

HKSE

12.6

HKD

Market price today

  • -5.6777

    P/E Ratio

  • 0.0426

    PEG Ratio

  • 27.42B

    MRK Cap

  • 0.00%

    DIV Yield

Shanghai Junshi Biosciences Co., Ltd. (1877-HK) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

-0.02%

Operating Profit Margin

-3.23%

Net Profit Margin

-3.15%

Return on Assets

-0.17%

Return on Equity

-0.26%

Return on Capital Employed

-0.23%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Cong Li
Full-time employees:2568
City:Shanghai
Address:Building 7
IPO:2018-12-24
CIK:

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.

General Outlook

When we look at how much money they make before expenses, they keep -0.024% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -3.231%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -3.152%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.168% return, is a testament to Shanghai Junshi Biosciences Co., Ltd.'s adeptness in optimizing resource deployment. Shanghai Junshi Biosciences Co., Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.264%. Furthermore, the proficiency of Shanghai Junshi Biosciences Co., Ltd. in capital utilization is underscored by a remarkable -0.229% return on capital employed.

Stock Prices

Shanghai Junshi Biosciences Co., Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $12.6, while its low point bottomed out at $12.16. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Shanghai Junshi Biosciences Co., Ltd.'s stock market.

Liquidity Ratios

Analyzing 1877.HK liquidity ratios reveals its financial health of the firm. The current ratio of 208.66% gauges short-term asset coverage for liabilities. The quick ratio (170.17%) assesses immediate liquidity, while the cash ratio (153.60%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio208.66%
Quick Ratio170.17%
Cash Ratio153.60%

Profitability Ratios

1877.HK profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -335.15% underscores its earnings before tax deductions. The effective tax rate stands at -2.09%, revealing its tax efficiency. The net income per EBT, 94.06%, and the EBT per EBIT, 103.72%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -323.13%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-335.15%
Effective Tax Rate-2.09%
Net Income per EBT94.06%
EBT per EBIT103.72%
EBIT per Revenue-323.13%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 2.09, it details the span from stock purchase to revenue. The 2 days it takes to settle debts showcases its creditor relations. Meanwhile, a 2 cash conversion cycle and 130.41% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding170
Days of Inventory Outstanding298
Operating Cycle577.42
Days of Payables Outstanding620
Cash Conversion Cycle-42
Receivables Turnover1.30
Payables Turnover0.59
Inventory Turnover1.23
Fixed Asset Turnover0.17
Asset Turnover0.05

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -1.70, and free cash flow per share, -2.64, depict cash generation on a per-share basis. The cash per share value, 4.67, showcases liquidity position. A payout ratio of -0.01 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, -2.58, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-1.70
Free Cash Flow per Share-2.64
Cash per Share4.67
Payout Ratio-0.01
Operating Cash Flow Sales Ratio-2.58
Free Cash Flow to Operating Cash Flow Ratio1.55
Cash Flow Coverage Ratio-0.57
Short Term Coverage Ratio-1.34
Capital Expenditure Coverage Ratio-1.80
Dividend Paid and Capex Coverage Ratio-1.76

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 24.22%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.42, we discern the balance between debt and equity financing. The long-term debt to capitalization, 19.61%, and total debt to capitalization, 29.78%, ratios shed light on its capital structure. An interest coverage of -116.29 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio24.22%
Debt Equity Ratio0.42
Long Term Debt to Capitalization19.61%
Total Debt to Capitalization29.78%
Interest Coverage-116.29
Cash Flow to Debt Ratio-0.57
Company Equity Multiplier1.75

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 1.52, provides a glimpse into top-line earnings distributed across each share. Net income per share, -2.32, reflects the portion of profit attributed to each share. The book value per share, 7.28, represents the net asset value distributed per share, while the tangible book value per share, 7.31, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share1.52
Net Income Per Share-2.32
Book Value Per Share7.28
Tangible Book Value Per Share7.31
Shareholders Equity Per Share7.28
Interest Debt Per Share1.84
Capex Per Share-0.84

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 3.38%, indicates top-line expansion, while the gross profit growth, -9.92%, reveals profitability trends. EBIT growth, 7.32%, and operating income growth, 7.32%, offer insights into operational profitability progression. The net income growth, 11.64%, showcases bottom-line expansion, and the EPS growth, 17.44%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth3.38%
Gross Profit Growth-9.92%
EBIT Growth7.32%
Operating Income Growth7.32%
Net Income Growth11.64%
EPS Growth17.44%
EPS Diluted Growth17.44%
Weighted Average Shares Growth7.39%
Weighted Average Shares Diluted Growth7.39%
Operating Cash Flow Growth-13.50%
Free Cash Flow Growth-31.27%
10-Year Revenue Growth per Share30760.93%
5-Year Revenue Growth per Share98176.54%
3-Year Revenue Growth per Share-21.41%
10-Year Operating CF Growth per Share-739.52%
5-Year Operating CF Growth per Share-141.00%
3-Year Operating CF Growth per Share-12.15%
10-Year Net Income Growth per Share-1234.14%
5-Year Net Income Growth per Share-94.56%
3-Year Net Income Growth per Share-14.28%
10-Year Shareholders Equity Growth per Share390.74%
5-Year Shareholders Equity Growth per Share31.86%
3-Year Shareholders Equity Growth per Share2.41%
Receivables Growth-6.65%
Inventory Growth-10.18%
Asset Growth-9.65%
Book Value per Share Growth-29.73%
Debt Growth35.34%
R&D Expense Growth-18.74%
SGA Expenses Growth8.28%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 15,366,112,768.389, captures the company's total value, considering both debt and equity. Income quality, 0.81, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.37, gauges operational efficiency, while the research and development to revenue, 128.95%, highlights investment in innovation. The ratio of intangibles to total assets, 1.18%, indicates the value of non-physical assets, and capex to operating cash flow, 41.32%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value15,366,112,768.389
Income Quality0.81
Sales General and Administrative to Revenue0.37
Research and Development to Revenue128.95%
Intangibles to Total Assets1.18%
Capex to Operating Cash Flow41.32%
Capex to Revenue-55.41%
Capex to Depreciation-274.58%
Stock-Based Compensation to Revenue1.53%
Graham Number19.47
Return on Tangible Assets-20.32%
Graham Net Net0.39
Working Capital3,074,671,000
Tangible Asset Value7,205,791,000
Net Current Asset Value1,527,571,000
Average Receivables500,448,971.5
Average Payables264,432,000
Average Inventory568,537,000
Days Sales Outstanding117
Days Payables Outstanding135
Days of Inventory On Hand294
ROIC-28.12%
ROE-0.32%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.67, and the price to book ratio, 1.67, reflect the market's valuation relative to the company's book value. The price to sales ratio, 39.92, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -9.94, and price to operating cash flows, -6.92, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio1.67
Price to Book Ratio1.67
Price to Sales Ratio39.92
Price Cash Flow Ratio-6.92
Price Earnings to Growth Ratio0.04
Enterprise Value Multiple-13.35
Price Fair Value1.67
Price to Operating Cash Flow Ratio-6.92
Price to Free Cash Flows Ratio-9.94
Price to Tangible Book Ratio2.42
Enterprise Value to Sales10.23
Enterprise Value Over EBITDA-7.15
EV to Operating Cash Flow-7.63
Earnings Yield-13.15%
Free Cash Flow Yield-16.41%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Shanghai Junshi Biosciences Co., Ltd. (1877.HK) on the HKSE in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -5.678 in 2024.

What is the ticker symbol of Shanghai Junshi Biosciences Co., Ltd. stock?

The ticker symbol of Shanghai Junshi Biosciences Co., Ltd. stock is 1877.HK.

What is company IPO date?

IPO date of Shanghai Junshi Biosciences Co., Ltd. is 2018-12-24.

What is company current share price?

Current share price is 12.600 HKD.

What is stock market cap today?

The market cap of stock today is 27424890297.000.

What is PEG ratio in 2024?

The current 0.043 is 0.043 in 2024.

What is the number of employees in 2024?

In 2024 the company has 2568.